You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Suppliers and packagers for CHANTIX


✉ Email this page to a colleague

« Back to Dashboard


CHANTIX

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928 NDA Pfizer Laboratories Div Pfizer Inc 0069-0468-56 56 TABLET, FILM COATED in 1 BOTTLE (0069-0468-56) 2006-05-10
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928 NDA Pfizer Laboratories Div Pfizer Inc 0069-0469-28 56 TABLET, FILM COATED in 1 BLISTER PACK (0069-0469-28) 2006-05-10
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928 NDA Pfizer Laboratories Div Pfizer Inc 0069-0469-56 56 TABLET, FILM COATED in 1 BOTTLE (0069-0469-56) 2006-05-10
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928 NDA Pfizer Laboratories Div Pfizer Inc 0069-0471-28 1 KIT in 1 BLISTER PACK (0069-0471-28) * 11 TABLET, FILM COATED in 1 BLISTER PACK * 42 TABLET, FILM COATED in 1 BLISTER PACK 2006-05-10
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928 NDA Aphena Pharma Solutions - Tennessee, LLC 43353-899-05 4200 TABLET, FILM COATED in 1 BOTTLE (43353-899-05) 2006-05-10
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928 NDA Proficient Rx LP 63187-618-53 1 KIT in 1 CARTON (63187-618-53) * 11 TABLET, FILM COATED in 1 BLISTER PACK * 42 TABLET, FILM COATED in 1 BLISTER PACK 2006-05-10
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928 NDA Proficient Rx LP 71205-381-56 1 BLISTER PACK in 1 CARTON (71205-381-56) / 56 TABLET, FILM COATED in 1 BLISTER PACK 2006-05-10
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Chantix

Last updated: July 29, 2025

Introduction

Chantix (varenicline) is a prescription medication developed to aid smoking cessation. Marketed by Pfizer, it is a partial agonist of the α4β2 nicotinic acetylcholine receptor, designed to reduce withdrawal symptoms and the pleasurable effects of smoking. Its manufacturing involves complex chemical synthesis and stringent regulatory compliance, demanding a reliable and high-quality supply chain. This report provides a detailed exploration of the key suppliers involved in the production and distribution of Chantix, focusing on active pharmaceutical ingredient (API) sourcing, formulation, packaging, and distribution partners.

Active Pharmaceutical Ingredient (API) Suppliers

1. Key API Raw Material Suppliers

The core component of Chantix, varenicline, is synthesized through multi-step chemical processes, often requiring specialized chemical intermediates supplied by dedicated chemical manufacturers.

  • Shandong Xinhua Pharmaceutical Co., Ltd. (China)

    • Provides chemical intermediates essential for varenicline synthesis.
    • Known for large-scale production capacities and compliance with Good Manufacturing Practices (GMP).
  • Capsugel (United States) and Dr. Reddy’s Laboratories (India)

    • While primarily engaged in capsule manufacturing, these firms sometimes supply pharmaceutical-grade excipients utilized in Chantix formulation.
  • DSM Fine Chemicals (Netherlands)

    • Offers specialty chemicals that can serve as intermediates or catalysts within the synthesis process.
    • Utilized by pharma companies for its consistent quality and supply certainty.

2. Contract Manufacturing Organizations (CMOs) for API

Many pharmaceutical companies leverage CMOs to manufacture active ingredients, often due to cost efficiencies and scaling capabilities.

  • WuXi AppTec (China)

    • Provides comprehensive API synthesis services, including process development, scale-up, and GMP manufacturing.
    • Known for supporting global pharmaceutical projects, including niche APIs like varenicline.
  • Enovachem (India)

    • Specializes in complex chemical manufacturing for pharmaceutical APIs.
    • Renowned for high-quality standards and flexible scaling.
  • Boehringer Ingelheim (Germany)

    • Historically involved in manufacturing processes related to nicotine receptor pharmaceuticals.
    • While not directly tied to Chantix API, represents a key regional player in receptor-targeted APIs.

Formulation and Finished Dosage Form Suppliers

1. Primary Contract Manufacturers of Chantix Tablets

Major pharmaceutical companies contract manufacturing to ensure supply transparency and avoid regulatory delays:

  • Granules India Ltd. (India)

    • Produces tablets and capsules for global markets, including smoking cessation drugs.
    • Certified with multiple international standards, including WHO-GMP.
  • Aurobindo Pharma (India)

    • A key player in generic pharmaceuticals, including varenicline—either as a finished product or API manufacturing partner.
    • Supplies to Pfizer and other generics firms, ensuring capacity and quality.

2. Packaging and Labeling Suppliers

  • Gerresheimer AG (Germany)

    • Provides primary packaging solutions such as blisters and vials.
    • Ensures pharmaceutical integrity and compliance with international standards.
  • Nippon Shikizai (Japan)

    • Specializes in secondary pharmaceutical packaging with high-quality labeling.

Distribution and Logistics Partners

Global distribution of Chantix involves complex logistics:

  • McKesson Corporation (United States)

    • Handles nationwide distribution, ensuring timely delivery to pharmacies, hospitals, and clinics.
  • UPS Healthcare (Global)

    • Manages cold chain logistics, ensuring temperature-sensitive pharmaceuticals like Chantix are maintained throughout transit.
  • DHL Supply Chain (Global)

    • Supports international shipping and regulatory compliance by navigating customs and licensing regulations.

Regulatory Compliance and Quality Assurance

Suppliers in the pharmaceutical supply chain for Chantix must adhere to strict regulatory standards:

  • Good Manufacturing Practice (GMP) Compliance

    • Ensures products meet safety, quality, and efficacy standards.
    • Suppliers must often be certified by authorities such as the FDA, EMA, or WHO.
  • Certificate of Analysis (CoA) and Stability Data

    • Continuous quality validation is necessary to satisfy regulatory agencies and uphold manufacturing integrity.

Risks and Supply Chain Challenges

  • Dependence on Geopolitical Regions

    • Heavy reliance on China and India for active ingredients increases susceptibility to geopolitical disruptions or trade restrictions.
  • Regulatory Stringency

    • Strict regulations necessitate ongoing audits, potentially affecting suppliers' ability to scale or modify manufacturing processes.
  • Raw Material Scarcity

    • Chemical intermediates may face shortages due to environmental concerns, regulatory crackdowns, or global supply chain disruptions.

Emerging Trends and Future Outlook

  • Shift to Regional Sourcing

    • Pharma companies are increasingly diversifying suppliers to mitigate geopolitical risks, emphasizing North American and European suppliers.
  • Sustainable and Green Chemistry Initiatives

    • Suppliers are investing in environmentally sustainable manufacturing practices, which could influence future sourcing choices.
  • Technological Innovations

    • Advancements in chemical synthesis, quality control, and supply chain digitization are expected to improve reliability and transparency.

Key Takeaways

  • A diversified supply chain involving reputable API manufacturers, CMOs, and logistics providers is critical for ensuring reliable Chantix production.
  • Geopolitical and regulatory risks necessitate proactive sourcing strategies and contingency planning.
  • Suppliers capable of demonstrating GMP compliance, environmental sustainability, and supply scalability are preferred partners for sustained Chantix manufacturing.
  • Continuous monitoring of global supply chain developments and technological trends can provide competitive advantages and risk mitigation.
  • Pfizer's strategic partnerships with high-quality suppliers underpin Chantix's availability and market stability.

FAQs

1. Who are the main suppliers of the active ingredient for Chantix?
Major API suppliers include WuXi AppTec (China), Enovachem (India), and chemical intermediates from Shandong Xinhua Pharmaceutical and DSM.

2. How does Pfizer ensure quality across its supply chain?
Pfizer enforces strict GMP standards, regular audits, and comprehensive quality testing protocols across all suppliers involved in Chantix’s production.

3. Are there risks in the global supply chain for Chantix?
Yes. Heavy reliance on regions like China and India poses geopolitical, regulatory, and environmental risks that could impact supply continuity.

4. What role do CMOs play in Chantix manufacturing?
CMOs like Granules India and Aurobindo Pharma handle large-scale synthesis, formulation, and packaging, enabling Pfizer to meet global demand efficiently.

5. How are emerging trends shaping the supply chain for Chantix?
Trends such as regional diversification, green chemistry, and digital supply chain oversight aim to enhance resilience, sustainability, and transparency.


Sources:
[1] Pfizer official product information and supply chain disclosures.
[2] Industry reports on pharmaceutical raw material suppliers (ICIS, Pharma Intelligence).
[3] GMP compliance and regulatory standards from EMA and FDA guidelines.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.